Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

This Phase 1 study is testing a new cancer drug called TGW101 in people with advanced solid tumors, including cancers of the breast, prostate, cervix, endometrium, stomach, lung, ovaries, and head and neck. The goal is to find the safest dose of TGW101 and to get early signals about whether it can shrink tumors. Adults aged 18 and older whose cancer has continued to grow despite standard treatments may be eligible if they have at least one measurable lesion and are in reasonably good overall health. Participation involves receiving TGW101 through infusion, regular clinic visits, blood tests, and imaging scans to monitor response and safety. This summary was prepared to help patients understand the study in plain language.